Cargando…
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach. BACKGROUND: Patients with relapsed or re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531864/ https://www.ncbi.nlm.nih.gov/pubmed/34690088 http://dx.doi.org/10.1016/j.clml.2021.09.018 |
_version_ | 1784801992726544384 |
---|---|
author | Moretti, Marina Liberati, Anna Marina Rigacci, Luigi Puccini, Benedetta Pulsoni, Alessandro Gini, Guido Galieni, Piero Fabbri, Alberto Cantonetti, Maria Pavone, Vincenzo Bolis, Silvia Botto, Barbara Renzi, Daniela Falchi, Lorenzo |
author_facet | Moretti, Marina Liberati, Anna Marina Rigacci, Luigi Puccini, Benedetta Pulsoni, Alessandro Gini, Guido Galieni, Piero Fabbri, Alberto Cantonetti, Maria Pavone, Vincenzo Bolis, Silvia Botto, Barbara Renzi, Daniela Falchi, Lorenzo |
author_sort | Moretti, Marina |
collection | PubMed |
description | In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach. BACKGROUND: Patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) have limited opportunities for curative therapy. High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) produces cure rates of 50% to 60%. Patients relapsing after, or ineligible for HDT-ASCT have limited therapeutic options and long-term remission is uncommon. Furthermore, few patients are candidate to allogeneic stem cell transplantation (AlSCT), a potentially curative approach. The combination of brentuximab vedotin and bendamustine (BVB) is a promising treatment for patients with R/R cHL, regardless of SCT eligibility. PATIENTS AND METHODS: We conducted a real-life study of BVB in 41 patients with R/R cHL after failure of ≥ 1 therapy including ASCT, AlSCT, or BV. RESULTS: Among 40 patients evaluable for efficacy, the overall response rate and complete response (CR) rate were 75% and 50%, respectively. No significant differences were observed between patients with primary refractory and relapsed disease, previously treated with ≤ 2 and ≥ 3 lines of therapy, or BV-exposed and BV-naïve. After a median follow-up of 38 months, the median progression free survival (PFS) for the entire population is 26 months; PFS is not reached, 10.5 months, and 4 months for patients achieving CR, partial response and no response, respectively (P < .0001). BVB was well tolerated and no grade 4 toxicity or new safety signals were observed. The most common treatment-emergent adverse events were infections. CONCLUSION: Our experience supports the efficacy and tolerability of the BVB combination in R/R cHL as a bridge to SCT, or as a definitive therapy for SCT-ineligible patients. Larger comparative studies testing BVB against standards of care are warranted in both settings. |
format | Online Article Text |
id | pubmed-9531864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-95318642022-10-04 Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience Moretti, Marina Liberati, Anna Marina Rigacci, Luigi Puccini, Benedetta Pulsoni, Alessandro Gini, Guido Galieni, Piero Fabbri, Alberto Cantonetti, Maria Pavone, Vincenzo Bolis, Silvia Botto, Barbara Renzi, Daniela Falchi, Lorenzo Clin Lymphoma Myeloma Leuk Article In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach. BACKGROUND: Patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) have limited opportunities for curative therapy. High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) produces cure rates of 50% to 60%. Patients relapsing after, or ineligible for HDT-ASCT have limited therapeutic options and long-term remission is uncommon. Furthermore, few patients are candidate to allogeneic stem cell transplantation (AlSCT), a potentially curative approach. The combination of brentuximab vedotin and bendamustine (BVB) is a promising treatment for patients with R/R cHL, regardless of SCT eligibility. PATIENTS AND METHODS: We conducted a real-life study of BVB in 41 patients with R/R cHL after failure of ≥ 1 therapy including ASCT, AlSCT, or BV. RESULTS: Among 40 patients evaluable for efficacy, the overall response rate and complete response (CR) rate were 75% and 50%, respectively. No significant differences were observed between patients with primary refractory and relapsed disease, previously treated with ≤ 2 and ≥ 3 lines of therapy, or BV-exposed and BV-naïve. After a median follow-up of 38 months, the median progression free survival (PFS) for the entire population is 26 months; PFS is not reached, 10.5 months, and 4 months for patients achieving CR, partial response and no response, respectively (P < .0001). BVB was well tolerated and no grade 4 toxicity or new safety signals were observed. The most common treatment-emergent adverse events were infections. CONCLUSION: Our experience supports the efficacy and tolerability of the BVB combination in R/R cHL as a bridge to SCT, or as a definitive therapy for SCT-ineligible patients. Larger comparative studies testing BVB against standards of care are warranted in both settings. 2022-03 2021-09-29 /pmc/articles/PMC9531864/ /pubmed/34690088 http://dx.doi.org/10.1016/j.clml.2021.09.018 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Article Moretti, Marina Liberati, Anna Marina Rigacci, Luigi Puccini, Benedetta Pulsoni, Alessandro Gini, Guido Galieni, Piero Fabbri, Alberto Cantonetti, Maria Pavone, Vincenzo Bolis, Silvia Botto, Barbara Renzi, Daniela Falchi, Lorenzo Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title | Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title_full | Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title_fullStr | Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title_full_unstemmed | Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title_short | Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience |
title_sort | brentuximab vedotin and bendamustine produce long-term clinical benefit in patients with relapsed or refractory classical hodgkin lymphoma: a multicenter real-life experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531864/ https://www.ncbi.nlm.nih.gov/pubmed/34690088 http://dx.doi.org/10.1016/j.clml.2021.09.018 |
work_keys_str_mv | AT morettimarina brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT liberatiannamarina brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT rigacciluigi brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT puccinibenedetta brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT pulsonialessandro brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT giniguido brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT galienipiero brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT fabbrialberto brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT cantonettimaria brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT pavonevincenzo brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT bolissilvia brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT bottobarbara brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT renzidaniela brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience AT falchilorenzo brentuximabvedotinandbendamustineproducelongtermclinicalbenefitinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaamulticenterreallifeexperience |